Politico  |  April 27, 2021

“I do think it’s going to play a larger role,” said Lawrence Gostin, a global health law professor at Georgetown University. “In the short to medium term, at least, the Johnson & Johnson vaccine has taken a reputational hit and people are more hesitant to take it. In addition, J&J has had major production problems at its Baltimore plant. And as a result I think Novavax is going to be a reasonably significant player.”

Read more here.